Korro Bio, Inc.

KRRO Nasdaq CIK: 0001703647

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 60 FIRST STREET, CAMBRIDGE, MA, 02141
Mailing Address 60 FIRST STREET, CAMBRIDGE, MA, 02141
Phone 617-468-1999
Fiscal Year End 1231
EIN 472324450

Financial Overview

FY2025 FY

$6.39M
Revenue
-$83.58M
Net Income

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment March 27, 2026 View on SEC
424B5 Prospectus supplement March 20, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 17, 2026 View on SEC
S-3 Shelf registration for future offerings March 13, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC
4 Insider stock transaction report March 12, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Successful merger with Legacy Korro, creating a focused genetic medicine company with a bolstered pipeline.
  • Proprietary ADAR-mediated RNA editing platform offers precise *in vivo* gene correction without altering DNA.
View Analysis

Material Events

8-K Strategy Change March 12, 2026
High Impact
  • Successful closing of an oversubscribed $85 million private placement financing.
  • Extended financial runway into the second half of 2028, significantly reducing financial risk.
View Analysis

Insider Trading

STRONG BUY 9 insiders 9 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.